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Aggregated α-synuclein and complex I deficiency:
exploration of their relationship in differentiated
neurons
AK Reeve*,1, MHR Ludtmann2, PR Angelova2, EM Simcox1, MH Horrocks3, D Klenerman3, S Gandhi2, DM Turnbull1 and AY Abramov*,2
α-Synuclein becomes misfolded and aggregated upon damage by various factors, for example, by reactive oxygen species. These
aggregated forms have been proposed to have differential toxicities and their interaction with mitochondria may cause dysfunction
within this organelle that contributes to the pathogenesis of Parkinson’s disease (PD). In particular, the association of α-synuclein
with mitochondria occurs through interaction with mitochondrial complex I and importantly defects of this protein have been
linked to the pathogenesis of PD. Therefore, we investigated the relationship between aggregated α-synuclein and mitochondrial
dysfunction, and the consequences of this interaction on cell survival. To do this, we studied the effects of α-synuclein on cybrid
cell lines harbouring mutations in either mitochondrial complex I or IV. We found that aggregated α-synuclein inhibited
mitochondrial complex I in control and complex IV-deficient cells. However, when aggregated α-synuclein was applied to complex
I-deficient cells, there was no additional inhibition of mitochondrial function or increase in cell death. This would suggest that as
complex I-deficient cells have already adapted to their mitochondrial defect, the subsequent toxic effects of α-synuclein are
reduced.
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The pathological hallmark of Parkinson’s disease (PD) is the
presence of α-synuclein aggregates, particularly within the
substantia nigra (SN). These aggregations take the form of
intracellular Lewy bodies, and also neuritic aggregations.
However, both the effect of these inclusions on neuronal
survival and the toxicity of different forms of α-synuclein are still
debated. To aggregate α-synuclein must undergo a conforma-
tional change, however, themechanismbehind this change and
subsequent aggregation in PD remains to be determined.
Mutations within the α-synuclein gene (SNCA (MIM
163890)) were the first to be associated with autosomal
dominant PD, while more recently genome-wide association
studies have suggested that single-nucleotide polymorphisms
in this gene are important for sporadic PD. Awidely expressed
protein α-synuclein is important for synaptic vesicle recycling
and the modulation of dopamine transmission within SN
neurons.1–8 It interacts with curved cellular membranes
including those of mitochondria suggesting a possible mode
of its toxicity,9–11 and can be imported into mitochondria in an
energy-dependent manner.9 The accumulation of α-synuclein
within mitochondria leads to complex I impairment, decreased
mitochondrial membrane potential (ΔΨm) and increased
reactive oxygen species (ROS) production. The occurrence
of these changes is also dependent on calcium
homoeostasis.9,12,13
Mitochondrial dysfunction has also been heavily implicated
in the pathogenesis of PD. Early studies showed a decrease in
mitochondrial complex I in the SN of PD patients and studies
involving the inhibition of this complex replicate many of the
features of this disease. In addition, SN neurons show high
levels of mitochondrial DNA deletions in old age,14,15 which
lead to respiratory deficiency, and the environment of the SN is
believed to be particularly oxidative due to a number of
processes, including the metabolism of dopamine. More
recently a number of genes known to cause autosomal
recessive forms of PD have been shown to encode proteins
with functions associated with mitochondrial turnover (Parkin/
Pink1 (MIM 602544, MIM 608309)) or oxidative stress (DJ-1
(MIM 602533)). However, the link between these two
processes and the loss of dopaminergic neurons in PD
remains to be elucidated.
Several hypotheses have been suggested for what might
cause α-synuclein to undergo the conformational change into
more aggregate prone forms, from oxidative stress to gene
mutations. Furthermore, the accumulation of mitochondrial
DNA (mtDNA) mutations and dysfunctional mitochondria with
advancing age are likely to have an effect on oxidative stress
levels within the SN, which might contribute further to the
misfolding and accumulation of this protein. Numerous studies
have used rotenone and other toxins to induce mitochondrial
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dysfunction and monitor the accumulation of α-synuclein,
despite the wealth of information that these studies provide
they often do not reflect the subtleties of the slowaccumulation
of mitochondrial dysfunction within ageing SN neurons.
Therefore, we investigated the relationship between mito-
chondria and aggregated α-synuclein, focussing on how these
forms affect neuronswith andwithoutmitochondrial dysfunction.
We wanted to understand how aggregated α-synuclein
impacted on the survival of cells with mitochondrial dysfunction,
to enable a deeper understanding of the effect of these two
processes on neuronal survival. To investigate thisweused cells
with mutations in and partial inhibition of complexes I and IV.
Results
Aggregated α-synuclein depolarises mitochondria
Changes in embryonic stem cell cybrids: Mitochondrial
membrane potential (Δψm) is an indicator of mitochondrial
function and health. Any changes in Δψm can modify cell
physiology and can be a trigger for pathology. We measured
the effect of aggregated α-synuclein on the Δψm of both
neurons and undifferentiated stem cells (Figures 1a and b).
Analysis of basal TMRM fluorescence in untreated cells
shows, consistent with previous data,16 that complex
I-deficient cybrid cells show an increased membrane
potential compared with controls (Figure 1c; n= 18 (taken
across three images), P=0.0004), whereas the Δψm of
complex IV-deficient cybrid cells is also greater than controls
(n= 18, Po0.0001). The basal membrane potential of
complex I-deficient cybrid cells is, however, not significantly
different to that of the complex IV-deficient cybrid cells
(n= 18, P=0.6017).
We applied a preparation of aggregated α-synuclein based
on the aggregation of fluorescently labelled α-synuclein
monomers, 50% labelled with Alexa Fluor 488 (FRET
(fluorescence resonance energy transfer) donor) and 50%
with Alexa Fluor 647 or Alexa Fluor 594 (FRETacceptors). As
oligomers form, they are statistically likely to contain both a
donor and acceptor label, and FRET is able to occur between
these allowing them to be separated from the vast majority of
monomeric protein making up the sample.We have previously
used this method to characterise in vitro aggregation of
labelled α-synuclein.17 This study demonstrated that globular
non-toxic oligomers are first formed which then structurally
convert to toxic, β-sheet containing oligomers, and ultimately
fibrils. For this study described, we halted aggregation at 29 h,
and single-molecule confocal FRET analysis confirms the
presence of ~ 0.8% oligomers (number of detected oligomers
as a fraction of total number of detected events). This
preparation of aggregated α-synuclein (mixture of 99%
monomeric and ~1% oligomeric α-synuclein) was used for
all the following experiments (with variation in the AF-label
used depending on the imaging experiment). The effects of
monomeric α-synuclein alonewere tested to distinguish it from
the action of the aggregated (oligomeric) peptide.
Following 24 h treatment with aggregated α-synuclein (100
nM), there is a significant reduction in Δψm of control and
complex IV-deficient cybrid cells (n=18, Po0.0001 from
160–55% (of control) for complex IV-deficient cybrid cells and
from 100–60% for controls; Figure 1e) when compared with
their untreated counterparts, whereas Δψm in the complex
I-deficient cybrid cells is not affected (n= 18, P=0.5270).
Changes in differentiated neurons: Complex I-deficient neu-
rons showed a significant increase in Δψm compared with
controls (n= 50, Po0.0001) and complex IV-deficient neu-
rons (n= 50, P= 0.0154; Figure 1d). Complex IV-deficient
neurons also show an increased Δψm compared with controls
(n= 40, P= 0.0010).
Twenty-four hours treatment with aggregated α-synuclein
(100 nM) produced a significant reduction in the mitochondrial
membrane potential of complex IV-deficient neurons (n= 40,
P= 0.0490, 131–112% (of control)), whereas the same
treatment caused significant increase in Δψm in control
neurons (n= 50, P=0.0186, 100–121%; Figure 1f), when
compared with their untreated counterparts. Again, no change
in Δψm was detected following the treatment of complex
I-deficient neurons (n=50, P= 0.0885).
Aggregated α-synuclein changes nicotinamide adenine
nucleotide (NADH) redox index. The redox state of
mitochondrial NADH is a function of respiratory chain activity
and substrate turnover. We measured the resting level of
NADH autofluorescence in differentiated neurons, which was
then expressed as the ‘redox index’, a ratio of the maximally
oxidised and maximally reduced signals.18 The dynamic
range of these signals was defined by obtaining the
maximally oxidised signal following treatment with 1 μM
carbonyl cyanide p-trifluoromethoxy-phenylhydrazone
(FCCP; which stimulates maximal respiration). Under these
conditions, mitochondrial NADH is fully oxidised and there-
fore defined as 0% reduced. The maximally reduced signal
was then defined as the response to 1mM NaCN (which fully
inhibits respiration preventing NADH oxidation), which pro-
motes maximal mitochondrial NADH reduction. Hence, under
these conditions NADH is taken as being 100% reduced.
The basal redox level in complex I-deficient neurons
(72.3±5.7; n=47; Po0.001) and complex IV-deficient
neurons (52.4±3.8%; n=76; Po0.001; Figure 2a) were
significantly higher when compared with control neurons
(34.6±2.2, n= 48). For investigation of the functional activity
of complex I, we used mitochondrial substrates and found that
5mM pyruvate increased the NADH level in control and
complex IV-deficient neurons but not in complex I-deficient
neurons (Figures 2b and d). Interestingly, me-succinate
caused oxidation of NADH in complex I- and IV-deficient
neurons (Figures 2c and d), but had no effect in control
neurons (Figure 2b). Thus, the increased NADH redox state in
neurons with complex I and IV mutation confirms inhibition of
respiration in these cells.
Application of aggregated α-synuclein (100 nM) induced an
increase in NADH autofluorescence in both control neurons
(by 31.6±2.6%, n=39) and cells with a complex IV deficiency
(by 28.3±2.9%, n=33), suggesting inhibition of respiration in
these cells but not in complex I-deficient cells (n=41;
Figures 2e and f). α-Synuclein is known to be inhibitor of
complex I.9,13 We can suggest, therefore, that the absence of
the effects of α-synuclein on NADH consumption in complex
I-deficient cells is because this complex is already inhibited in
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mitochondria of these cells, because of the two mtDNA
mutations within these cells.
Effect of aggregated α-synuclein on cellular respiration.
Using the Seahorse analyser (XFe24) we estimated the effect
of aggregated α-synuclein on the respiration of neurons. The
basal rate of respiration in neurons with complex I or complex
IV deficiency was lower than in control neurons (Figures 3a
and b) in both untreated cells and following 15min pre-
incubation of the neurons with aggregated α-synuclein
Figure 1 α-Synuclein affects mitochondrial membrane potential. TMRM fluorescence was used to quantify mitochondrial membrane potential in undifferentiated stem cells
(a) and neurons (b) from complex I- and complex IV-deficient cybrids and in control cell lines. (b) When identifying neurons a brightfield image is used to allow the morphology of
the neurons to be assessed, (c) Z-Stacked images show that the neurons lie in a different focal plane to non-neuronal cells. Mitochondria are only analysed from neurons. Basal
TMRM fluorescence was measured (d) showing increased mitochondrial membrane potential in the complex I (**P= 0.0004) and complex IV (***Po0.0001) stem cells
compared with controls. (f) Membrane potential was measured again following 24 h treatment with aggregated α-synuclein. α-Synuclein significantly reduced the membrane
potential of complex IV-deficient cybrids and control stem cells (***Po0.0001) but had no effect on the membrane potential of complex I-deficient cybrid stem cells. Basal TMRM
fluorescence was measured in neurons (e) and showed increased mitochondrial membrane potential in the complex I-deficient neurons compared with the controls
(***Po0.0001) and complex IV-deficient neurons (*P= 0.0154) and between the complex IV-deficient neurons and the control cells (**P= 0.001). (g) Membrane potential was
measured again following 24 h treatment with aggregated α-synuclein. α-Synuclein did not affect complex I-deficient neurons but reduced the membrane potential of complex IV-
deficient neurons (+P= 0.0490) and increased that of the control neurons (*P= 0.0186). Scale bar represents 10 μm
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(40 nM; three replicates per cell line). α-Synuclein had no
effect on the basal rate of respiration of neurons with complex
I or complex IV deficiency but reduced FCCP-induced
maximal respiration in complex IV-deficient neurons
(Figures 3c and d). Aggregated α-synuclein did not induce
uncoupling in complex I- or complex IV-deficient cells
(Figure 3e) but reduced the ratio of oligomycin-dependent
and basal respiration that is more likely due to inhibition of the
basal rate of respiration and not to the protonophoretic
activity of the peptide (because it is absent in mutated cells).
In addition, we can show that treatment with aggregated α-
synuclein causes complex IV-deficient cells to become more
glycolytic (Figure 3f), whereas decreasing the aerobic
respiration of control cell lines and importantly showing very
little effect on the complex I-deficient neurons.
Aggregated α-synuclein affects the level of ATP in
neurons. The ability of α-synuclein to inhibit mitochondrial
Figure 2 Effect of α-synuclein on NADH redox state in cells with mitochondrial mutations and control neurons. Estimation of the percentage change in mitochondrial
NADH pool in control cells—control (b), complex I deficient (c) and cells with a deficiency of complex IV (d). (a) Redox state was estimated as: 0 is response to FCCP
(maximal rate of respiration and lowest level of mitochondrial NADH) and 100% is response to cyanide (inhibition of respiration with no consumption of NADH in
mitochondria); complex I- and complex IV-deficient neurons have higher NADH redox state compared with control neurons (**Po0.001). Treatment with 100 nM α-synuclein
increased both the level of NADH autofluorescence within WT neurons and the redox state (e). (f) How the effect of α-synuclein treatment on WT neurons compares to
neurons with mitochondrial deficiencies. An increase in NADH autofluorescence following treatment is recorded in complex IV-deficient neurons suggesting CI inhibition, but
not in complex I-deficient neurons.**Po0.001
α-Synuclein and complex I
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respiration may induce changes in [ATP]. We measured ATP
levels inside neurons using a genetically encoded fluorescent
ATP indicator (AT1.03),19 which we have previously and
successfully used in primary neurons.20 We found that the
basal level of ATP is lower in complex I-deficient neurons
compared with control cells (1.43±0.11 ATP ratio; n= 9,
compared with 1.78±0.12 in controls; Po0.001). [ATP] in
neurons with a complex IV defect was also decreased
compared with controls (1.41±0.14 ratio compared with
1.78±0.12, n= 8; Po0.001; Figures 4a and c). Application
of aggregated α-synuclein (100 nM) significantly reduced
the ATP level within control neurons (by 20%) or complex
IV-deficient neurons (by 8%) but not in complex I-deficient
neurons (Figures 4a and c). Subsequent application
of inhibitors of oxidative phosphorylation and glycolysis
(2 μg/ml oligomycin and 20 μM iodoacetic acid) blocked ATP
production and induced a reduction in the ATP level of control
neurons. Importantly, oligomycin induced an almost complete
decrease of neuronal ATP in control cells suggesting that
these cells produce ATP predominantly by oxidative phos-
phorylation. The effect of oligomycin was significantly smaller
in complex IV-deficient neurons with a higher reliance on
glycolysis. In complex I-deficient neurons, the effect of
oligomycin was directly opposite to that on control cells—it
Figure 3 α-Synuclein affects the cellular respiration of neurons. Using a Seahorse extracellular flux analyser we examined the cellular respiration of neurons in the presence
of aggregated α-synuclein. Oxygen consumption rates were measured at regular intervals with the addition of compounds to test mitochondrial activity, in (a) the absence or (b)
presence of a 15-min pre-incubation with 40 nM aggregated α-synuclein. (c) Basal respiration is decreased in control neurons following treatment with aggregated α-synuclein.
(d) Maximal respiration is also decreased following treatment in control and complex IV-deficient neurons. (e) ATP production through oxidative phosphorylation is also decreased
in control cells upon treatment while it increases in complex IV neurons. Neurons harbouring a complex I defect show no changes in cellular respiration following treatment with
aggregated α-synuclein. (f) Treatment with aggregated α-synuclein increases glycolysis in complex IV-deficient neurons, whereas have little effect on complex I-deficient neurons.
Three replicates per cell line were performed
α-Synuclein and complex I
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increased the ATP level, suggesting that complex V is
working in reverse mode in these cells and is therefore,
consuming ATP for the maintenance of Δψm. This finding
confirms our previous observation of the effect of oligomycin
on mitochondrial membrane potential.16 Thus, the effect of α-
synuclein on the ATP level in cells with complex I mutation is
less likely to be an initial trigger for neuronal cell death.
The effect of aggregated α-synuclein on ROS production.
Previously, we have shown that mitochondrial ROS is a main
trigger for neuronal loss in cells with a complex I defect,16 and
that oligomeric α-synuclein can induce cell death through
induction of lipid peroxidation,21 therefore, we assessed the
rate of hydrogen peroxide (H2O2) production, using the
Hyper-3 genetic quantitative probe.22 In agreement with our
previous publication, we observed that the basal level of
H2O2 was significantly higher in complex I-deficient neurons
(3.4±0.26 Hyper-3 ratio, n=4 experiments compared with
0.58±0.04, n= 4; in control; Po0.001; Figures 5a and b).
Hydrogen peroxide production in complex IV-deficient neu-
rons was also increased compared with control neurons
(1.4±0.11 Hyper-3 ratio; n=4; Po0.05; Figure 5c). Aggre-
gated α-synuclein (100 nM) induced a similar increase in the
H2O2 production of control neurons and cells with a complex I
deficiency (Figures 5a and c). Note that effect of α-synuclein
was not due to pH changes since the ROS independent but
pH-dependent construct shows no changes in response to
synuclein or hydrogen peroxide treatment (Figure 5a, grey
line). Thus, α-synuclein induces similar changes in ROS
production in all cell groups.
α-Synuclein does not cause increased cell death in cells
with a complex I deficiency. To measure the effects of
α-synuclein on cell survival, we treated undifferentiated and
neuronal cells with 500 nM aggregated α-synuclein for 24 h,
following this, cells were loaded with Hoechst, to give total
cell counts, and propidium iodide (PI), to give counts of dead
cells. Using this approach we calculated the percentage cell
death that had occurred following treatment and because of
the uptake of PI we could measure those cells that had died
via necrosis (Figure 6). Using brightfield images we could
also compare the amount of neuronal cell death that had
occurred versus the death of other cell types within the
culture. This experiment revealed that aggregated α-synuclein
treatment drastically increases the amount of cell death for
control neurons (n= 5 images, n=~4300 cells), with cell
death doubling from 8 to 16% (P=0.0016) following 24 h
incubation with aggregated α-synuclein (Figure 6a). However,
incubation with aggregated α-synuclein did not cause an
increase in neuronal cell death of complex I- or complex
Figure 4 α-Synuclein affects the ATP production within neurons. Cytosolic ATP concentration in (a) control, (b) complex IV and (c) complex I-deficient neurons transfected
with AT1.03. ATP levels are measured as the level of fluorescence and the ratio of the 527/475 nm signal in neurons after inhibition of oxidative phosphorylation by oligomycin
(2 μg/ml) and glycolysis by iodoacetic acid (IAA—20 μM) following treatment of the cells with 100 nM α-synuclein. Basal levels of ATP are lower in cells with an inherent
mitochondrial deficiency compared with control neurons. Treatment of neurons with aggregated α-synuclein causes a reduction in ATP levels in control neurons and those with a
complex IV deficiency, but not in complex I-deficient neurons
α-Synuclein and complex I
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IV-deficient cell lines (Figure 6a; n=5 images, n=~2500
(complex I, P=0.992) and ~ 7200 (complex IV, P=0.457)).
Furthermore, we can look at total cell death including
undifferentiated cells within the same culture and a similar
observation was made, 24 h treatment with aggregated
α-synuclein cause a significant increase in cell death for
control cells (n=5 images, n=1700) with the percentage cell
death rising from 5.8 to 14.5% (P= 0.0001). Consistent with
the neuronal data there was no increase in total cell death
recorded for complex I- (P=0.54) or complex IV- (P=0.27)
deficient cells. These data are consistent with other experi-
mental data, which suggest that since oligomers inhibit
complex I they are not detrimental to cells already harbouring
a complex I defect. These data suggest that α-synuclein and
mitochondrial defects (due to mitochondrial DNA mutations)
within the same cell do not cause necrotic cell death.
Discussion
Both α-synuclein and mitochondrial dysfunction have been
proposed to be important for the loss of dopaminergic, SN
neurons in PD and studies have suggested that inhibition of
mitochondrial complex I is fundamental to this loss. We aimed
to further understand the relationship between mitochondria,
aggregated α-synuclein and cell death by studying the effects
of aggregated α-synuclein on neurons with deficiencies in
mitochondrial complex I or IV. The α-synuclein used in these
experiments is based on an aggregation procedure that
generates a mixture of monomers and oligomeric forms, as
previously described,17 in a 99% to 1% ratio. The oligomeric
species have been characterised to be compact β-sheet
structure oligomers. We utilised this mixed species prepara-
tion as it most accurately reflects the endogenous α-synuclein
within the intracellular environment in PD, that is, a mixture of
species that are predominantly monomeric with a small
Figure 5 α-Synuclein affects ROS production within neurons. The level of
intracellular hydrogen peroxide after application of 100 nM α-synuclein to (a) control
neurons, (b) complex IV- or (c) complex I-deficient neurons. The grey trace in a
represents Hyper- C199S ratio under application of α-synuclein and hydrogen
peroxide. The basal level of ROS production was higher in neurons with a complex I
or IV deficiency compared with control cells. Treatment with aggregated α-synuclein
caused an increase in ROS production in control neurons and those with a complex I
deficiency
Figure 6 α-Synuclein does not affect the survival of neurons with mitochondrial
defects. Using the ratio of Hoechst to propidium iodide staining, we estimated cell
death following treatment with aggregated α-synuclein in both (a) neurons and (b) the
total cell population. Treatment with 500 nM α-synuclein for 24 h was associated with
increased cell death in control cells but not in cells with an inherent mitochondrial
defect. **P= 0.0016, ***P= 0.0001
α-Synuclein and complex I
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proportion of presumed highly toxic β-sheet oligomers.
Furthermore, we are able to determine the specific effect of
the oligomers within the preparation by performing monomer
only experiments. These data show that aggregated forms of
α-synuclein inhibit complex I of the electron transport chain,
have little effect on cells with inherent complex I deficiency and
importantly do not cause cell death in these neurons.
Aggregated α-synuclein impairs mitochondrial function
through complex I inhibition. α-Synuclein is capable of
inducing mitochondrial defects in several models where
mutant α-synuclein is overexpressed, for example, Martin
et al have shown that overexpression of α-synuclein reduces
activity of mitochondrial complex IV.23 Although mutant
α-synuclein is capable of binding to voltage-dependent anion
channels and interacting with the mitochondrial adenylate
translocator to facilitate mitochondrial permeability transition
pore opening and modulation of the PD phenotype in
experimental mice.24,25 The dysfunction induced in isolated
mitochondria by oligomeric forms of α-synuclein is both
complex I-dependent and calcium-mediated,13 whereas mice
that overexpress α-synuclein show age dependent, differen-
tial defects of mitochondrial respiration in different brain
areas.26 These effects on mitochondrial complex I have been
shown to be ameliorated by overexpression of TOM20.27
Mutated forms of α-synuclein cause mitochondrial structural
changes, particularly affecting the cristae,28 whereas Droso-
phila models have highlighted the contribution of oxidative
stress to the neuronal changes seen, for example, the
expression of human α-synuclein bearing the A53T or A30P
mutations leads to hypersensitivity to hypoxia.29 Although
transgenic mice expressing mutant forms of α-synuclein have
also been generated, they often do not show SN dopami-
nergic neuronal loss despite very severe phenotypes and
neuron loss in other brain regions.23
Here we investigate the interaction of α-synuclein with
mitochondria in more detail and show that aggregated
α-synuclein reduces mitochondrial membrane potential, inhi-
bits mitochondrial respiration and ATP production in control
cells, but not in those with a complex I defect. The complex I
cybrids used in this study have previously been shown to have
adapted to their deficiency by upregulating mitochondrial
membrane potential through the reversal of complex V.16 This
means that further inhibition via aggregated α-synuclein has
little impact on the function or survival of these cells. Previous
studies using these cells have also shown that the level of
ROS production within these cybrids is higher than in control
cell lines.16 We show here that aggregated α-synuclein further
increases the production of ROS within these cell lines, but
again that there is no enhancement of the effect in complex
I-deficient cells.
Acute complex I inhibition by α-synuclein causes cell
loss, but not in neurons with inherent, chronic complex I
deficiency. These data are consistent with previous studies
that investigated the effect of α-synuclein on human
dopaminergic neurons.9 The import of α-synuclein into
mitochondria is an energy-dependent process requiring an
intact membrane potential,9 thus despite the respiratory
defects within the complex I-deficient cells import of
α-synuclein is still possible due to the increase in membrane
potential of these cells. Importantly, we show that the
combination of mitochondrial dysfunction and inherent
complex I deficiency is not sufficient to cause neuronal loss.
Acute complex I inhibition, such as occurs following
α-synuclein treatment, does cause neuronal loss, but long-
term chronic complex I inhibition, such as may occur during
ageing, is not associated with cell death in the presence of
α-synuclein.
A reduction in complex I activity and expression has been
reported in the SN of patient’s with PD and inhibitors of this
complex (such as rotenone and mitochondrial permeability
transition pore) induce a parkinsonian phenotype in animal
models,30–32 change the expression of α-synuclein33 and
effect the aggregation of α-synuclein even in the absence of
mitochondrial complex I.34 Therefore, the inhibition of complex
I by aggregating α-synuclein could be a key step in the
pathogenesis of PD. Our data suggest that although complex I
defects are detrimental to cells, the accumulation of
α-synuclein does not enhance any defects when differentiated
neurons have an existing inhibition of complex I. In culture,
these cells have adapted their physiology to be able to survive,
predominantly through the reversal of the ATP synthase
(complex V), therefore further inhibition of complex I by
aggregated α-synuclein does not have a toxic effect. Complex
I inhibition by α-synuclein is more marked in control cells and
those with a complex IV defect as these neurons have not
encountered such inhibition before and are therefore more
sensitive.
Conclusions
Aggregated α-synuclein inhibits mitochondrial complex I
leading to reduced respiration and ATP production in neurons
alongside an increase in ROS production. A pre-existing
deficiency in complex I does not enhance these defects.
Materials and Methods
α-Synuclein. All forms of α-synuclein used in this study were generated by our
collaborators, the manufacture and purification of this protein are detailed in
Cremades et al.17
Cell culture. The cell lines used in this study have been previously described.35
All cybrid lines were derived from the parental line CC9.3.1, used as the control for
this study. Cybrids were generated with a severe complex I deficiency due to two
homoplasmic mtDNA mutations in complex I (m.13887Cins in MTND6 and
m.12273G4A in MTND5) and with a mild complex IV deficiency due to a
homoplasmic mtDNA mutation in MTCO1 (m.6589T4C). The cells were passaged
and differentiated as previously described 35 and using the 4+/4− method.36
Measurement of mitochondrial membrane potential. Mitochondrial
membrane potential (Δψm) measurements were made for untreated cells as a
baseline and those treated with aggregated forms of α-synuclein as described
previously.16 Briefly, measurements were made on cells loaded with 25 nM
tetramethylrhodamine methyl ester (TMRM, Life Technologies, Pisley, Scotland, UK)
for 40 min before imaging in Hank’s balanced salt solution (Life Technologies),
25 nM TMRM was maintained for imaging. TMRM fluorescence intensity was
quantified by measuring the peak TMRM fluorescence intensity for single
mitochondria within a given cell. For each cell line and treatment, a minimum of
three images were taken and within each image a minimum of six measurements of
distinct mitochondrial regions were taken to give n= 18.
α-Synuclein and complex I
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Measurement of cellular respiration. Mitochondrial respiratory activity
was measured in live neurons in a Seahorse XFe24 extracellular flux analyser
(Seahorse Bioscience, North Billerica, MA, USA). Neurons were seeded onto a 24-
well plate (50 000 cells/well) 24 h before the experiment. Growth media were
replaced with basic experimental media (plus glucose) supplemented with FBS to
2% and 10 mM pyruvate (pH 7.4) 1 h before the experiment and the neurons
incubated in a CO2-free atmosphere. Measurements of O2 consumption rate (OCR)
and extracellular acidification rate were taken, mitochondrial activity was tested
using: oligomycin (to 1.3 μM, an ATP synthase inhibitor), carbonyl cyanide
p-trifluoromethoxy-phenylhydrazone (FCCP, a respiratory chain uncoupler to drive
maximum respiratory capacity (5 μM), rotenone (1 μM, a complex I inhibitor) and
finally antimycin A (to 1 μM), which blocks complex III.37 Data were normalised by
cell number, and a number of parameters were assessed, including basal
respiration, maximal respiration following FCCP treatment and ATP production by
oxidative phosphorylation which was calculated by multiplying ATP turnover ((basal
OCR—NMR)—(oligomycin-inhibited OCR – NMR)) by the established phosphorus/
oxygen (P/O) ratio of 2.3.38 A total of three replicates per cell line were performed.
Measurement of NADH /redox indexes. NADH autofluorescence was
measured using a Zeiss 710 VIS CLSM (Carl Zeiss Microscopy, Munich, Germany)
equipped with a META detection system and a x40 oil immersion objective. Membrane
potential, ROS production, intracellular ATP and cell death measurements were all
taken using this microscopy setup. For NADH autofluorescence, excitation light of
405 nm and emitted fluorescence measured at 420–450 nm. Illumination intensity was
kept to a minimum (at 0.1–0.2% of laser output) to avoid phototoxicity and the pinhole
set to give an optical slice of ~ 2 μm. The addition of FCCP (final concentration 2 μM)
gave maximal respiration, whereas 1 mM cyanide elicited minimal respiration. Data
were then normalised to data from untreated control cells and the NADH mitochondrial
pool and percentage redox indexes calculated.
Measurement of ROS. For intracellular H2O2 assessments, cells were
transfected with the Hyper-3 construct or the Hyper-CS control pH probe using
Effectene according to the manufacturers’ instructions (Qiagen, Manchester, UK).
Importantly, due to the toxicity of the Effectene reagent in combination with
Neurobasal A media (Life Technologies), cells were exposed to the transfection
complexes for an hour before the media were replaced with normal Neurobasal A
growth medium. Cells were then left to express the constructs for 48 h before
experiments were performed. Hyper-3 or Hyper-C199S fluorescence was excited at
488 and 405 nm and emission set at 510–540 nm and expressed as 488/405 ratio.
Imaging of intracellular ATP levels with FRET-based genetically
encoded indicator AT1.03. Cells were transfected with AT1.03 and
mitAT1.03 plasmids (Addgene, Cambridge, MA, USA) as described above.
Measurements of ATP levels with AT1.03 and mitAT1.03 were performed on a
confocal microscope and images were obtained using a x63 oil immersion objective
to allow measuring the fluorescent signal immediately over dendrites. Cyan
fluorescent protein was excited with 405 nm, and emission from 460 to 510 nm was
scanned. The 405-nm laser line was used to excite yellow fluorescent protein, which
was measured using a bandpass filter from 515 to 580 nm. Illumination intensity
was kept to a minimum (at 0.1–0.2% of laser output) to avoid phototoxicity and the
pinhole set to give an optical slice of ∼ 2 μm.
Cell death. Following 24 h of treatment with α-synuclein cell death was
estimated using Hoechst (Life Technologies) and propidium iodide (Life
Technologies). The cells were incubated with 2 μM propidium iodide and 5μM
Hoechst in Hank’s balanced salt solution for 30 min. Single images were then
captured, five per cell line, the total number of dead cells (propidium iodide positive)
counted and the percentage cell death calculated as a percentage of the total cells
(Hoechst positive).
Statistical analysis. Data sets were tested for normality using the
Kolmogorov–Smirnov, D’Agostino and Pearson omnibus and Shapiro–Wilk tests.
Normal data sets were then analysed for statistical significance using a paired t-test
and non-normal sets using a Mann–Whitney U-test.
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